Katrin Rupalla
Director/Board Member at 4D PHARMA PLC
Profile
Katrin Rupalla is the founder of Ymmunobio AG, a company founded in 2021.
She holds the title of Scientific Advisory Board.
She currently holds multiple positions, including Independent Non-Executive Director at 4D Pharma Plc since 2020, Director at The Cancer Drug Development Forum, and Head-Regulatory Affairs at Speedel Pharma AG.
In her former roles, Dr. Rupalla served as Chairman at Ambrx Biopharma Cayman, Inc. from 2022 to 2023, Director at Ambrx, Inc., Director at Iqure Pharma, Inc. from 2020 to 2021, Independent Director at ZyVersa Therapeutics, Inc. in 2023, Vice President & Head-Regulatory Oncology at Bristol Myers Squibb Co. from 2018 to 2019, SVP, Head-Regulatory, MedDoc, R&D Quality at H.
Lundbeck A from 2019 to 2021, and Vice President-Regulatory Sciences at Bristol-Myers Squibb Holdings Ltd.
from 2012 to 2015.
Dr. Rupalla's education includes an MBA from Jones International University and graduate and doctorate degrees from Philipps University of Marburg.
Katrin Rupalla active positions
| Companies | Position | Start |
|---|---|---|
| 4D PHARMA PLC | Director/Board Member | 2020-09-22 |
Speedel Pharma AG
 Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | General Counsel | - |
Ymmunobio AG
 Ymmunobio AG BiotechnologyHealth Technology Ymmunobio AG is a Swiss preclinical stage oncology biotech company that develops innovative treatments for cancer patients through new classes of antibodies. The company is based in Riehen, Switzerland. The company focuses on high unmet need indications in gastro-intestinal cancers, making extensive progress in developing first-in-class or novel class of antibodies that have the potential to overcome resistance of cancer patients to current available therapies. Ymmunobio's research is based on their deep understanding of immuno-oncology and precision cancer treatments, leveraging their profound knowledge of biologics while selecting the optimal approach to developing transformative therapeutics across cancer indications. The company was founded in 2021 by Katrin Rupalla. The CEO is Peter Schiemann. | Founder | 2021-11-30 |
| The Cancer Drug Development Forum | Director/Board Member | - |
Former positions of Katrin Rupalla
| Companies | Position | End |
|---|---|---|
| ZYVERSA THERAPEUTICS, INC. | Director/Board Member | 2023-05-17 |
Ambrx Biopharma, Inc.
 Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Chairman | 2023-05-17 |
| H. LUNDBECK A/S | Corporate Officer/Principal | 2021-11-30 |
Iqure Pharma, Inc.
 Iqure Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Iqure Pharma, Inc. is a biotech company that develops therapeutics for patients and physicians. The company is based in Wilmington, DE. The company was founded by Pawel Zolnierczyk, Henk de Wilde, Peter Schiemann, Anna Rzewuska. Pawel Zolnierczyk has been the CEO since incorporation. | Director/Board Member | 2021-03-31 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 2019-06-30 |
Training of Katrin Rupalla
| Jones International University | Masters Business Admin |
| Philipps University of Marburg | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| H. LUNDBECK A/S | Health Technology |
| 4D PHARMA PLC | Health Technology |
| ZYVERSA THERAPEUTICS, INC. | Finance |
| Private companies | 7 |
|---|---|
Bristol-Myers Squibb Holdings Ltd.
 Bristol-Myers Squibb Holdings Ltd. MiscellaneousMiscellaneous Part of Bristol Myers Squibb Co., Bristol-Myers Squibb Holdings Ltd. is a holding British company. The private company is based in Uxbridge, UK. | Miscellaneous |
Ambrx, Inc.
 Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | Health Technology |
| The Cancer Drug Development Forum | |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Health Technology |
Iqure Pharma, Inc.
Iqure Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Iqure Pharma, Inc. is a biotech company that develops therapeutics for patients and physicians. The company is based in Wilmington, DE. The company was founded by Pawel Zolnierczyk, Henk de Wilde, Peter Schiemann, Anna Rzewuska. Pawel Zolnierczyk has been the CEO since incorporation. | Commercial Services |
Ymmunobio AG
Ymmunobio AG BiotechnologyHealth Technology Ymmunobio AG is a Swiss preclinical stage oncology biotech company that develops innovative treatments for cancer patients through new classes of antibodies. The company is based in Riehen, Switzerland. The company focuses on high unmet need indications in gastro-intestinal cancers, making extensive progress in developing first-in-class or novel class of antibodies that have the potential to overcome resistance of cancer patients to current available therapies. Ymmunobio's research is based on their deep understanding of immuno-oncology and precision cancer treatments, leveraging their profound knowledge of biologics while selecting the optimal approach to developing transformative therapeutics across cancer indications. The company was founded in 2021 by Katrin Rupalla. The CEO is Peter Schiemann. | Health Technology |
- Stock Market
- Insiders
- Katrin Rupalla
